Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how providing adult smokers with access to multiple tobacco flavor options in an electronic nicotine delivery system ENDS affects their ability to quit smoking over a 13-week period. This open-label, single-arm study involves healthy adults who regularly smoke combustible cigarettes. The study compares outcomes with data from a previous trial that offered only a single tobacco flavor. Participants receive an ENDS device with a choice of three different tobacco flavor options. They are allowed to select their preferred flavors during the study. This study is conducted at multiple sites and does not include a placebo or control group in the current phase, but comparisons will be made to an earlier randomized controlled trial with a single-flavor option. Participants are involved for 13 weeks during which their smoking abstinence is assessed. They will complete questionnaires via a smartphone application and may receive notifications to assist with study activities. Researchers will measure the impact of flavor access on smoking cessation rates, complete switching to ENDS, and abstinence differences between flavor groups. The study monitors participant adherence and evaluates safety throughout the period.
Actively Recruiting
Researchers are evaluating outcomes in female patients with acute thoracolumbar compression fractures, focusing on how pain is managed and how well patients can function after injury. This observational study tracks patients whose fractures occurred within the last 3 months or less. The study aims to measure pain levels using the Numeric Rating Scale NRS and Brief Pain Inventory BPI, and quality of life through the PROMIS questionnaire at multiple time points before and after intervention. Participants will receive treatment using the commercially available SPRINT Peripheral Nerve Stimulation PNS system for 60 days. Pain and quality of life will be assessed prior to the intervention, then again at 2 weeks, 3 months, and 6 months after PNS implantation. The primary focus is on pain reduction, while secondary outcomes include improvements in function and quality of life as reported by participants through digital data collection. During the study, participants will complete assessments of pain and function at specified intervals. These include questionnaires like the PROMIS and patient-reported outcome measures collected via CareSense, a digital system. Researchers will monitor changes in pain scores and quality of life over time. The total participation includes assessments up to 6 months following the nerve stimulation treatment, allowing for observation of both short- and longer-term effects.
Actively Recruiting
Researchers are evaluating UX016, an oral drug, for its safety, appropriate dosing, and impact on muscle strength in adults aged 18 to 55 with GNE Myopathy GNEM. This rare muscle disorder is confirmed by genetic testing and is characterized by muscle weakness, particularly in the upper extremities. The study is a randomized, double-blind, placebo-controlled trial led by Ultragenyx Pharmaceutical Inc to assess these outcomes over an extended period. Participants will be randomly assigned in a 31 ratio to receive either UX016 or a placebo. Depending on their sub-cohort, they may receive one or two initial single doses of UX016 at varying amounts before starting daily dosing, or proceed directly to daily dosing at a set dose of either 1g or 2g. After 48 weeks of daily dosing, all participants have the option to enter an extension phase where everyone receives UX016. Placebo recipients also have the chance to receive UX016 during this extension. Throughout the study, participants will undergo various assessments including muscle strength tests like the Upper Extremity Composite score and functional activities scale, as well as plasma and urine tests to monitor UX016 and sialic acid levels. Safety is closely monitored by tracking treatment-emergent adverse events up to week 96, covering both the double-blind and extension periods. The study includes muscle biopsies and requires participants to be able to walk independently at screening. The total study duration extends up to December 2028.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether the DeepMSI AI system can detect biomarkers of age-related macular degeneration AMD with sensitivity and specificity comparable to those of experienced clinicians. This observational study focuses on adults over 40 years old and aims to determine if AI analysis of retina images matches clinical interpretations. The study is sponsored by AI-Spectral and seeks to improve AMD detection using advanced imaging technology. Participants eyes will be imaged using the MSI-120 retina imaging device, and the images will be analyzed independently by the DeepMSI AI system and retina specialists. The study includes two groups eyes with AMD-related changes such as drusen or geographic atrophy, and healthy eyes from participants over 40 without any AMD or other retinopathies. AI results will not be shared with participants or treating clinicians during the study to avoid influencing care. Participants will have their retina images collected and analyzed, with researchers comparing AI and clinician findings to assess equivalency in detecting AMD biomarkers. The primary outcome is the comparison of sensitivity and specificity between DeepMSI AI and clinicians over an average follow-up of six months. The study involves no treatment administration, focusing solely on imaging and data collection during the participation period.
Actively Recruiting
Researchers are evaluating the effectiveness of combining transcranial direct current stimulation tDCS with mindfulness techniques delivered remotely via telemedicine in adults diagnosed with unipolar depression. This study involves 25 participants and aims to understand how this combined approach may impact depressive symptoms. It is a randomized, double-blind, sham-controlled trial sponsored by Soterix Medical. Participants will be assigned to one of two groups one receiving active tDCS along with audio mindfulness instruction and music, and the other receiving sham placebo electrical stimulation combined with the same mindfulness audio guidance. The study uses a parallel-arm design to compare these interventions over the course of treatment. The primary treatment period includes assessments at Week 4 and Week 7. During the study, participants will complete various assessments including the Hamilton Depression Rating Scale HDRS, Quick Inventory of Depressive Symptomatology-Self Report QIDS-SR, Clinical Global Impression scales, Sheehan Disability Scale, and Montgomery-Asburg Depression Rating Scale. These evaluations occur at multiple time points from baseline through Week 13. Safety and blinding integrity will also be monitored. The total study participation lasts around 13 weeks, with regular remote monitoring and questionnaires to track depressive symptoms and overall functioning.